Med Tech-related technology assessments and clinical guidelines from NICE in February 2023


Mar 2023

In February 2023, NICE published two Interventional Procedures Guidance (IPG):

  • Transvenous obliteration for gastric varices;
  • Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer.

IPG is developed for most of the novel interventional procedures entering the English market. The program focuses solely on clinical evidence. Recommendations may vary from "for research only" to "for use with standard arrangements for clinical governance, consent, and audit." Recommendations are not binding, although they are followed by providers and commissioners.

NICE made the following conclusions:

In February 2023, NICE published the first Health Technology Evaluation (HTE) for medical technologies. HTE is a new type of NICE guidance that uses the Early Value Assessment (EVA) approach to provide rapid conditional recommendations on promising health technologies that have the potential to address the unmet national need. NICE evaluates available evidence to determine if earlier patient and system access in the NHS is appropriate while further evidence is generated.

NICE recommended four guided self-help digital cognitive behavioural therapy (CBT) to be used as an initial treatment option for children and young people (aged 5 to 18) with mild to moderate symptoms of anxiety or low mood while evidence is being generated. These technologies can be used once they have Digital Technology Assessment Criteria (DTAC) approval from NHS England. The technologies are:

  • Lumi Nova (by BfB labs);
  • Online Social anxiety Cognitive therapy for Adolescents (by OSCA);
  • Online Support and Intervention for child anxiety (by OSI);
  • Space from anxiety for teens, space from the low mood for teens, space from low mood and anxiety for teens (by Silvercloud).

The MedTech Innovation Briefings (MIBs) is the advice program of NICE for innovative technologies. It provides an overview of clinical effectiveness, safety, and cost. It does not offer formal guidance, and it, therefore, does not provide any recommendations. The two new MIBs published in February 2023 are:

  • LIVERFASt for assessing and monitoring liver fibrosis, activity, and steatosis in people with non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), hepatitis B and hepatitis C;
  • Ambu aScope 4 RhinoLaryngo for visualizing upper airway anatomy during rhino-laryngoscopy procedures in adults.

One new clinical guideline, “Barrett's oesophagus and stage 1 oesophageal adenocarcinoma monitoring and management,” was published in February 2023, including recommendations on endoscopic and non-endoscopic treatment. One clinical guideline, “Cardiovascular disease: risk assessment and reduction, including lipid modification,” was updated.

See the full details for guidance here and for MIBs here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).

The latest related news


Mar 2023

In February 2023, the Scottish Health Technology Group, SHTG, released three MedTech-related assessments: selective internal radiation therapies (SIRT) for treating primary hepatocellular carcinoma, Feeling Good app, store-and-forward teledermatology for triage of primary care referrals.

Read more


Mar 2023

A new preeclampsia screening algorithm has been evaluated within the "New Method" framework since 2021. The algorithm helps to predict the risk of preeclampsia in the first trimester based on several parameters, including ultrasound examination and measurement of the Placenta Growth Factor (PIGF). In March 2023, the Decision Forum for "New Method" was held and commissioned to perform the implementation study of a new screening algorithm at St. Olav's Hospital.

Read more


Mar 2023

On March 1, 2023, Belgian National Institute for Health and Disability Insurance (INAMI-RIZIV) updated three Articles of the Nomenclature related to in-vitro diagnostics. Twelve new codes concerning clinical biology, molecular biology for infections, and genetics were implemented.

Read more


Mar 2023

In January-February 2023, Health Technology Wales published sixteen Medtech-related Topic Exploration Reports (TER), including stereotactic radiosurgery, percutaneous implantation of pulmonary artery pressure sensors, ambulatory patch ECG devices, and others; however, Health Technology Wales will not proceed with full appraisals on these topics. No Guidance was released for Medtech in January-February 2023.

Read more


Mar 2023

In March 2023, a new ‘AI and Digital Regulations Service’ for developers and adopters of artificial intelligence (AI) and digital technologies was launched in England. Four organizations provide this multi-agency advisory service: NICE, Care Quality Commission, Medicines and Healthcare products Regulatory Agency, and Health Research Authority. The website is currently in public beta and focused on information for developers.

Read more